Death from myocardial infarction and related cardiovascular events remains the number one cause of death in the Western world. Proper preclinical models are essential in order to study the efficacy of potential pharmacological agents which may have novel potential for treatment and/or prevention of ischemic heart disease.
The canine model of infarction resembles the diseased human heart in terms of size and the development of coronary collateral blood vessels. The canine heart’s size and circulation are suitable not only for assessment of infarct size, but also for catheterization of the major coronary arteries for localized administration of test compounds.
The rabbit and rat models of infarction present the advantages of being less expensive and can accommodate larger cohorts of animals. Properly designed, these models can be used to test sparse collateral circulation to isolate drug effects to the ischemic region of interest – preventing confounding cardioprotective effects resulting from increasing coronary collateral blood flow.
- Measurement of the myocardial segment shortening (%SS)
- Regional myocardial blood flow
- Release of Troponin C from the ischemic area
Dog, Rabbit, Rat.